An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2019
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REGARD
- Sponsors Bayer
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Jun 2018 Planned End Date changed from 30 May 2018 to 14 Jun 2018.
- 11 May 2018 Planned End Date changed from 15 Apr 2018 to 30 May 2018.